|
May 4
|
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?
|
|
May 4
|
Eli Lilly Raised Its Outlook. Is the Stock a Buy Now?
|
|
May 3
|
Amazon Stock Is on a Roll. Here’s Why It’s on This Firm’s ‘Best Ideas List.’
|
|
May 3
|
Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market
|
|
May 3
|
Analyst unveils Amgen stock price target after weight-loss drug data
|
|
May 3
|
Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
|
|
May 3
|
Weight-loss drug competition heats up. Is Wegovy in trouble?
|
|
May 3
|
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
|
|
May 3
|
Amgen Knocks Novo Nordisk's Ozempic Stock Rally. Its Stock Is Flying.
|
|
May 3
|
US STOCKS-Wall St set to open sharply higher on soft jobs data
|
|
May 3
|
Amgen shares soar as executives outline obesity drug push
|
|
May 3
|
US STOCKS-Futures rise on Apple, Amgen boost; jobs data awaited
|
|
May 3
|
How the CFOs of Eli Lilly and Novo Nordisk are coping with ‘unprecedented demand’ for weight-loss drugs
|
|
May 2
|
1 Wall Street Analyst Thinks Eli Lilly Stock Is Going to $892. Is It a Buy?
|
|
May 2
|
Analysts reveal Eli Lilly stock price targets after earnings
|
|
May 2
|
Weight Loss Competition Heats Up In Britain, Online Pharmacies Slash Prices for Wegovy and Mounjaro
|
|
May 2
|
Amgen Soars After CEO Gives Update on Experimental Obesity Drug
|
|
May 2
|
Market Chatter: Novo Nordisk, Eli Lilly's Weight-Loss Drugs Get Price Cuts in UK
|
|
May 2
|
Earnings Season: 3 Companies Boosting Guidance
|
|
May 2
|
Novo Nordisk’s Wegovy Sales More Than Doubled. Why the Stock Is Falling.
|